Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. frebt

FrEBT

Improving diagnostics of respiratory diseases and boosting the COMAC MEDICAL Ltd. competitiveness and growth by validation of fractional EBT biomarker through new method of measurement and device

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 FrEBT project word cloud

Explore the words cloud of the FrEBT project. It provides you a very rough idea of what is the project "FrEBT" about.

service    doctors    5    medical    fractional    socio    patients    diagnosis    10    economic    exhaled    pulmonary    diagnostic    morbidity    breath    eu28    population    elderly    prognostic    validate    million    precise    mln    phase1    network    people    bln    share    organizational    monitoring    innovative    specialists    inflammatory    prove    solution    asia    bulgaria    vulnerable    mortality    trials    groups    full    clinical    15    technological    total    region    deaths    118    380    competitiveness    workforce    annually    specialisation    20    profitability    financial    sme    young    cancer    global    outcome    worldwide    assessing    pulmonology    lives    market    12    diseases    gps    countries    commercial    invasive    innovation    biomarker    organization    regions    niche    alternative    launch    respiratory    ltd    saving    obstructive    comac    device    oncology    risk    14    painful    stages    temperature    ip    healthcare    description    managerial    feasibility    lung    filling    children    causing    disruptive    faster    markets   

Project "FrEBT" data sheet

The following table provides information about the project.

Coordinator		 COMAC MEDICAL LTD 

Organization address
address: 131 ODRIN STR AP 22
city: SOFIA
postcode: 1303
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Bulgaria [BG]
 Project website http://comac-medical.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    COMAC MEDICAL LTD BG (SOFIA) coordinator 50˙000.00

Map

 Project objective

The innovation project objectives are to: 1/prove through a feasibility study the potential to validate the Fractional Exhaled Breath Temperature, via new viable and disruptive technological device, as a diagnostic, prognostic and monitoring biomarker for inflammatory and obstructive pulmonary diseases; 2/enhance the competitiveness and profitability of the full- service clinical research organization COMAC MEDICAL Ltd., operating via own network of partners in 14 countries from 3 European regions with population of over 118 mln. The commercial potential of the innovative solution is that it is a best alternative of the existing methods on market, saving great number of diagnosis‘ stages without any potential risk for the patients, being more precise, user friendly, non-invasive, less painful, faster, cost effective, covering vulnerable groups of children, young and elderly people, saving lives, increasing workforce capabilities. It is a response to the EU wide and global challenges related to the respiratory diseases causing high level of morbidity and mortality–at about 1 million deaths annually in the European Region; 2/3 of them in EU28, with total cost there of € 380 bln. The expected SME growth is 20%, leading to specialisation in Pulmonology and Oncology and filling a market niche. The SME will launch into new markets in Europe and Asia, increasing its market share in clinical trials - 12-15% in Bulgaria;10% in Europe and 2-5% worldwide. The outcome of the Phase1 project is a feasibility study, assessing the socio-economic, commercial, technical aspects of the innovation, based on 6 steps of activities on: the Description of the innovative solution;Market/Technical Feasibility;Financial/Economic Feasibility; Organizational/Managerial Feasibility;Risk assessment;IP Management. The targeted users are the patients through the healthcare systems and the doctors, specialists in respiratory diseases and lung cancer as well as the GPs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FREBT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FREBT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More